Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE™, a new treatment in the fight against opioid addiction, is now being implanted in patients across the country.
Approved by Health Canada in April 2018, PROBUPHINE™ is the only subdermal implant designed to deliver buprenorphine continuously for 6 months following a single treatment. The product must be inserted and removed by a healthcare professional who has successfully completed a live training program, the PROBUPHINE Education Program.
Knight has the exclusive right to distribute PROBUPHINE™ in Canada under a license agreement with Titan Pharmaceuticals, Inc. (NASDAQ:TTNP).
“Probuphine provides a unique new option in the treatment of opioid abuse, one that overcomes the barriers of daily adherence and multiple pharmacy and clinic visits,” said Dr. Ken Lee, London site lead and head physician at the Rapid Access Addiction Medicine (RAAM) Clinic.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.